{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:03Z","timestamp":1769817603974,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.steroids.2017.08.012","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T20:30:58Z","timestamp":1504297858000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Corticosteroid inhibits chemokines production in systemic sclerosis patients"],"prefix":"10.1016","volume":"127","author":[{"given":"Andr\u00e9a Tavares","family":"Dantas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anderson Rodrigues","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Clara Pinheiro Duarte","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Ferraz","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurindo Ferreira","family":"da Rocha Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla Stela Santana","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelly Cristiny","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moacyr Jesus Barreto","family":"de Melo Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Diniz Lopes","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"da Rocha Pitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Luzia Branco Pinto","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira Galdino","family":"da Rocha Pitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2017.08.012_b0005","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar2821","article-title":"Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations","volume":"11","author":"Gourh","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.steroids.2017.08.012_b0010","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.autrev.2010.09.016","article-title":"Fibrosis and immune dysregulation in systemic sclerosis","volume":"10","author":"Chizzolini","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.steroids.2017.08.012_b0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2011.01.013","article-title":"Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis","volume":"139","author":"Fenoglio","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.steroids.2017.08.012_b0020","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/00002281-200311000-00015","article-title":"The role of chemokines in the pathogenesis of scleroderma","volume":"15","author":"Atamas","year":"2003","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2249.2004.02642.x","article-title":"Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement","volume":"138","author":"Scala","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.steroids.2017.08.012_b0030","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/s10165-012-0795-6","article-title":"Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study","volume":"23","author":"Hasegawa","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0035","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.berh.2011.11.002","article-title":"Glucocorticoids","volume":"25","author":"Spies","year":"2011","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tem.2012.11.005","article-title":"The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore","volume":"24","author":"Busillo","year":"2013","journal-title":"Trends Endocrinol. Metab."},{"issue":"Suppl 2","key":"10.1016\/j.steroids.2017.08.012_b0045","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar4685","article-title":"The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis","volume":"16","author":"Cutolo","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.steroids.2017.08.012_b0050","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/jir.1998.18.1059","article-title":"Glucocorticoid-induced type 1\/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction","volume":"18","author":"Agarwal","year":"1998","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.steroids.2017.08.012_b0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/107999001750133159","article-title":"Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines","volume":"21","author":"Agarwal","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.steroids.2017.08.012_b0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/B:IFLA.0000033023.76110.51","article-title":"Modulation of cytokine-induced production of IL-8 in vitro by interferons and glucocorticosteroids","volume":"28","author":"Nyhl\u00e9n","year":"2004","journal-title":"Inflammation"},{"key":"10.1016\/j.steroids.2017.08.012_b0065","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/CVI.00404-09","article-title":"Delayed addition of glucocorticoids selectively suppresses cytokine production in stimulated human whole blood","volume":"17","author":"Horton","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.steroids.2017.08.012_b0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10067-013-2422-0","article-title":"Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries","volume":"33","author":"Iudici","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0075","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2634","article-title":"High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy","volume":"11","author":"Hunzelmann","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.steroids.2017.08.012_b0080","doi-asserted-by":"crossref","first-page":"103118","DOI":"10.1016\/j.rdc.2015.08.011","article-title":"Corticosteroids in myositis and scleroderma","volume":"42","author":"Postolova","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.steroids.2017.08.012_b0085","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00296-010-1697-6","article-title":"Corticosteroids and the risk of scleroderma renal crisis: a systematic review","volume":"32","author":"Trang","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.steroids.2017.08.012_b0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.steroids.2017.08.012_b0095","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00300808","article-title":"Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis \u2013 a randomized placebo-controlled study","volume":"14","author":"Sharada","year":"1994","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.steroids.2017.08.012_b0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jdermsci.2004.03.001","article-title":"Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis","volume":"35","author":"Fujii","year":"2004","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.steroids.2017.08.012_b0110","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-4362.1995.tb04664.x","article-title":"Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis","volume":"34","author":"Pai","year":"1995","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0115","first-page":"84","article-title":"The modified rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis","volume":"25","author":"Furst","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0120","article-title":"Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series","volume":"31","author":"Montanelli","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2249.1999.00929.x","article-title":"Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibros","volume":"117","author":"Hasegawa","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.steroids.2017.08.012_b0130","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/1529-0131(200106)44:6<1382::AID-ART231>3.0.CO;2-T","article-title":"Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression","volume":"44","author":"Galindo","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.steroids.2017.08.012_b0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/ard.2006.067967","article-title":"Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?","volume":"67","author":"Carulli","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.steroids.2017.08.012_b0140","article-title":"CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment","volume":"30","author":"Bandinelli","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/art.21497","article-title":"Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells","volume":"54","author":"Distler","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.steroids.2017.08.012_b0150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/bjo.82.3.318","article-title":"Orbital fibroblast chemokine modulation: effects of dexamethasone and cyclosporin A","volume":"82","author":"Burnstine","year":"1998","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.steroids.2017.08.012_b0155","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2249.2005.02770.x","article-title":"Increased expression of chemokines in patients with Wegener\u2019s granulomatosis \u2013 modulating effects of methylprednisolone in vitro","volume":"140","author":"Torheim","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.steroids.2017.08.012_b0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/rheumatology\/ken401","article-title":"Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis","volume":"48","author":"Distler","year":"2009","journal-title":"Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0165","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.4049\/jimmunol.163.10.5686","article-title":"IFN-{gamma}-inducible protein-10 attenuates Bleomycin-induced pulmonary Fibrosis via inhibition of Angiogenesis","volume":"163","author":"Keane","year":"1999","journal-title":"J Immunol."},{"key":"10.1016\/j.steroids.2017.08.012_b0170","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.4049\/jimmunol.1402008","article-title":"CXCL9 regulates TGF-beta1-induced epithelial to Mesenchymal transition in human Alveolar Epithelial Cells","volume":"195","author":"O\u2019Beirne","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.steroids.2017.08.012_b0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kem313","article-title":"CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study","volume":"47","author":"Antonelli","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.steroids.2017.08.012_b0180","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cyto.2010.01.009","article-title":"Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"50","author":"Antonelli","year":"2010","journal-title":"Cytokine"},{"key":"10.1016\/j.steroids.2017.08.012_b0185","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1196\/annals.1321.010","article-title":"Glucocorticoids and the Th1\/Th2 balance","author":"Elenkov","year":"2004","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.steroids.2017.08.012_b0190","first-page":"374","article-title":"Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications","author":"Elenkov","year":"1996","journal-title":"Proc. Assoc. Am. Physicians"},{"key":"10.1016\/j.steroids.2017.08.012_b0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","article-title":"Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids","volume":"211","author":"Ramesh","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.steroids.2017.08.012_b0200","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/ker227","article-title":"Glucocorticoids enhance Th17\/Th1 imbalance and signal transducer and activator of transcription 3 expression in systemic lupus erythematosus patients","author":"Prado","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.steroids.2017.08.012_b0205","first-page":"821","article-title":"Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses","volume":"18","author":"Kirkham","year":"1991","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0210","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/gut.45.3.382","article-title":"Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes","volume":"45","author":"Hearing","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.steroids.2017.08.012_b0215","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1164\/rccm.200512-1930OC","article-title":"Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma","volume":"174","author":"Hew","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.steroids.2017.08.012_b0220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/rheumatology\/40.3.267","article-title":"Glucocorticoid-mediated repression of inflammatory cytokine production in fibroblast-like rheumatoid synoviocytes is independent of nuclear factor-kappaB activation induced by tumour necrosis factor alpha","volume":"40","author":"Han","year":"2001","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.steroids.2017.08.012_b0225","first-page":"46","article-title":"Effects of dexamethasone on lymphocyte proliferation and cytokine production in rheumatoid arthritis","volume":"29","author":"De","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.steroids.2017.08.012_b0230","first-page":"1","article-title":"Use of biologics and other novel therapies for the treatment of systemic sclerosis","volume":"13","author":"Bruni","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.steroids.2017.08.012_b0235","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X1730154X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X1730154X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:09:35Z","timestamp":1692961775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X1730154X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":47,"alternative-id":["S0039128X1730154X"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2017.08.012","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroid inhibits chemokines production in systemic sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2017.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}